JP6184982B2 - 点眼用抗体含有徐放性製剤 - Google Patents

点眼用抗体含有徐放性製剤 Download PDF

Info

Publication number
JP6184982B2
JP6184982B2 JP2014555204A JP2014555204A JP6184982B2 JP 6184982 B2 JP6184982 B2 JP 6184982B2 JP 2014555204 A JP2014555204 A JP 2014555204A JP 2014555204 A JP2014555204 A JP 2014555204A JP 6184982 B2 JP6184982 B2 JP 6184982B2
Authority
JP
Japan
Prior art keywords
formulation
hexpla
mol
esba903
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014555204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505551A5 (enExample
JP2015505551A (ja
Inventor
ジョン グリムショー，
ジョン グリムショー，
ルッツ アスムス，
ルッツ アスムス，
ミヒャエル メラー，
ミヒャエル メラー，
ロベール ギュルニイ，
ロベール ギュルニイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech An Alcon Biomedical Research Unit LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech An Alcon Biomedical Research Unit LLC filed Critical Esbatech An Alcon Biomedical Research Unit LLC
Publication of JP2015505551A publication Critical patent/JP2015505551A/ja
Publication of JP2015505551A5 publication Critical patent/JP2015505551A5/ja
Application granted granted Critical
Publication of JP6184982B2 publication Critical patent/JP6184982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014555204A 2012-02-02 2013-01-31 点眼用抗体含有徐放性製剤 Active JP6184982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594099P 2012-02-02 2012-02-02
US61/594,099 2012-02-02
PCT/EP2013/051907 WO2013113820A1 (en) 2012-02-02 2013-01-31 Antibody-containing sustained-release formulation for ocular administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017130349A Division JP2017165784A (ja) 2012-02-02 2017-07-03 点眼用抗体含有徐放性製剤

Publications (3)

Publication Number Publication Date
JP2015505551A JP2015505551A (ja) 2015-02-23
JP2015505551A5 JP2015505551A5 (enExample) 2016-01-14
JP6184982B2 true JP6184982B2 (ja) 2017-08-23

Family

ID=47748581

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014555204A Active JP6184982B2 (ja) 2012-02-02 2013-01-31 点眼用抗体含有徐放性製剤
JP2017130349A Withdrawn JP2017165784A (ja) 2012-02-02 2017-07-03 点眼用抗体含有徐放性製剤
JP2019036141A Pending JP2019081797A (ja) 2012-02-02 2019-02-28 点眼用抗体含有徐放性製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017130349A Withdrawn JP2017165784A (ja) 2012-02-02 2017-07-03 点眼用抗体含有徐放性製剤
JP2019036141A Pending JP2019081797A (ja) 2012-02-02 2019-02-28 点眼用抗体含有徐放性製剤

Country Status (5)

Country Link
US (4) US20130202605A1 (enExample)
EP (1) EP2809344B1 (enExample)
JP (3) JP6184982B2 (enExample)
ES (1) ES2604837T3 (enExample)
WO (1) WO2013113820A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113820A1 (en) * 2012-02-02 2013-08-08 Esbatech - A Novartis Company Llc Antibody-containing sustained-release formulation for ocular administration
WO2019217785A1 (en) 2018-05-10 2019-11-14 St. Jude Children's Research Hospital, Inc. High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro
GB202116442D0 (en) 2021-11-15 2021-12-29 Actome Gmbh High-efficacy labeling of antibodies with oligonucleotide labels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE330631T1 (de) * 1999-01-05 2006-07-15 Univ Southern Australia Antikörperfragmente zur lokalen behandlung von augenerkrankungen
AU775778B2 (en) * 1999-01-05 2004-08-12 Flinders University Of South Australia, The Novel agents and methods for treatment and diagnosis of ocular disorders
ATE497405T1 (de) * 2005-03-11 2011-02-15 Potentia Pharmaceuticals Inc Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration
ES2646141T3 (es) * 2005-04-22 2017-12-12 Universite De Geneve Composiciones de poliláctido y usos de las mismas
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
IN2012DN00407A (enExample) * 2009-08-05 2015-08-21 Pieris Ag
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
WO2013113820A1 (en) * 2012-02-02 2013-08-08 Esbatech - A Novartis Company Llc Antibody-containing sustained-release formulation for ocular administration

Also Published As

Publication number Publication date
ES2604837T3 (es) 2017-03-09
EP2809344B1 (en) 2016-08-24
US20150044213A1 (en) 2015-02-12
US20160362483A1 (en) 2016-12-15
US10093726B2 (en) 2018-10-09
WO2013113820A1 (en) 2013-08-08
JP2017165784A (ja) 2017-09-21
US9873736B2 (en) 2018-01-23
JP2019081797A (ja) 2019-05-30
US20130202605A1 (en) 2013-08-08
EP2809344A1 (en) 2014-12-10
JP2015505551A (ja) 2015-02-23
US20180362630A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
Kanwar et al. In situ forming depot as sustained-release drug delivery systems
Ibrahim et al. An overview of PLGA in-situ forming implants based on solvent exchange technique: effect of formulation components and characterization
CN110475545B (zh) 用于控制释放生物活性剂的可注射和可生物降解的聚合物制剂
US9168221B2 (en) Functionalised triblock copolymers and compositions containing such polymers
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
KR102552356B1 (ko) 보툴리눔 독소의 효능 증대를 위한 생분해성 폴리머 제제
CN111107840A (zh) 药物组合物
EP2624813B1 (en) Composition for intraocular implantation of bevacizumab
JP7636334B2 (ja) 治療物質の眼投与のための薬物送達組成物及びその使用法
TW201417831A (zh) 用於持續釋放蛋白質之可生物降解的藥物傳遞系統
JP2022547162A (ja) 抗ＩＬ－２３ｐ１９抗体製剤
CN108697810A (zh) 用于剂的控制释放的聚合物复合材料
Patel et al. Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries
CA3008491A1 (en) Sustained release cyclosporine-loaded microparticles
JP2019081797A (ja) 点眼用抗体含有徐放性製剤
WO2017015616A1 (en) Ocular protein delivery
Bisht et al. Injectable in-situ gel depot system for targeted delivery of biologics to the retina
Asmus et al. Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment
CN114401716A (zh) 持续释放的曲前列环素-化合物微粒组合物
US20250073179A1 (en) Formulations comprising a therapeutic protein and at least one stabilizer
Ye et al. Thermogelling copolymers for medical applications
Marques et al. PKPD of PLGA-PEG-PLGA Copolymeric Micelles
Jung Development and Characterization of LM22A-4 loaded Polymer Microparticles for Treating Spinal Cord Injury
Singh et al. In Situ Forming Phase–inversion injectable Hydrogels for Controlled Drug Release

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170726

R150 Certificate of patent or registration of utility model

Ref document number: 6184982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250